Kiran Krishnamachari
Research Subjects
Kiran Krishnamachari has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Anders Jacobsen Skanderup
Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore
2 shared publications Anna Gan
Genome Institute of Singapore (GIS), Agency for Science, Technology, and Research (A*STAR), Singapore, Singapore
1 shared publication- Hanaé Carrié
Genome Institute of Singapore (GIS), Agency for Science, Technology, and Research (A*STAR), Singapore, Singapore
1 shared publication Huu An Bui Nguyen
Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
1 shared publication- Iain Beehuat Tan
Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
1 shared publication Jet Ong Tze
Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
1 shared publication
Latest Publications
- Open Access
- 9 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Improved tumor-only variant calling and mutation burden estimation with VarNet-T
Somatic variant calling algorithms typically detect mutations in cancer genomes by comparing sequence data from a tumor sample against a matched normal sample. However, matched normal samples are often unavailable in clinical diagnostics or retrospective analyses of archival tumor samples in biobanks, compromising variant calling accuracy due to the difficulty in distinguishing somatic mutations from germline mutations or sequencing artifacts. Here, we introduce VarNet-T, an end-to-end weakly supervised deep learning framework for accurately identifying somatic variants from aligned tumor reads without a matched normal sample. VarNet-T is trained using millions of high-confidence variants and benchmarked using public datasets, demonstrating 20-33% performance improvement over existing methods. We assess the accuracy of tumor mutation burden (TMB) estimation on 1000 tumor samples spanning 10 solid cancer types. Compared to existing methods, VarNet-T demonstrates >3x higher accuracy in TMB-high status classification, suggesting significant potential to improve patient selection for immunotherapy. Overall, the improved accuracy of VarNet-T has the potential to enhance the utility of tumor-only sequencing in cancer research and clinical molecular diagnostics.
- 9 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessImproved tumor-only variant calling and mutation burden estimation with VarNet-T
Somatic variant calling algorithms typically detect mutations in cancer genomes by comparing sequence data from a tumor sample against a matched normal sample. However, matched normal samples are often unavailable in clinical diagnostics or retrospective analyses of archival tumor samples in biobanks, compromising variant calling accuracy due to the difficulty in distinguishing somatic mutations from germline mutations or sequencing artifacts. Here, we introduce VarNet-T, an end-to-end weakly supervised deep learning framework for accurately identifying somatic variants from aligned tumor reads without a matched normal sample. VarNet-T is trained using millions of high-confidence variants and benchmarked using public datasets, demonstrating 20-33% performance improvement over existing methods. We assess the accuracy of tumor mutation burden (TMB) estimation on 1000 tumor samples spanning 10 solid cancer types. Compared to existing methods, VarNet-T demonstrates >3x higher accuracy in TMB-high status classification, suggesting significant potential to improve patient selection for immunotherapy. Overall, the improved accuracy of VarNet-T has the potential to enhance the utility of tumor-only sequencing in cancer research and clinical molecular diagnostics.
- Open Access
- 18 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA
Detection of somatic mutations in cell-free DNA (cfDNA) is challenging due to low variant allele frequencies and extensive DNA degradation. Here we develop a benchmarking strategy using longitudinal patient-matched cfDNA samples from individuals with colorectal and breast cancer. Samples with high and ultra-low levels of tumor-derived DNA are combined into controlled dilution series that preserve the properties of authentic cell-free DNA, including each patient’s germline and blood-cell mutation backgrounds. Using deep whole-genome (150x) and exome (2,000x) sequencing, we define a reference set of ~37,000 single nucleotide variants and ~58,000 indels to benchmark nine somatic variant callers across varying ctDNA levels and sequencing depths. We also explore machine learning–based tuning of individual callers and identify features that improve accuracy in cfDNA. This benchmarking resource clarifies the detection limits of current approaches and provides practical guidance for selecting somatic variant calling methods in liquid biopsy applications.
- 18 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessComprehensive benchmarking of methods for mutation calling in circulating tumor DNA
Detection of somatic mutations in cell-free DNA (cfDNA) is challenging due to low variant allele frequencies and extensive DNA degradation. Here we develop a benchmarking strategy using longitudinal patient-matched cfDNA samples from individuals with colorectal and breast cancer. Samples with high and ultra-low levels of tumor-derived DNA are combined into controlled dilution series that preserve the properties of authentic cell-free DNA, including each patient’s germline and blood-cell mutation backgrounds. Using deep whole-genome (150x) and exome (2,000x) sequencing, we define a reference set of ~37,000 single nucleotide variants and ~58,000 indels to benchmark nine somatic variant callers across varying ctDNA levels and sequencing depths. We also explore machine learning–based tuning of individual callers and identify features that improve accuracy in cfDNA. This benchmarking resource clarifies the detection limits of current approaches and provides practical guidance for selecting somatic variant calling methods in liquid biopsy applications.